

Dr. Deepti Parashar, Scientist E



Date of Birth: 1976-11-20
Date of Joining ICMR: 14th Nov, 2006
Date of Joining Present Post: 1st Sep, 2018

Address (off): ICMR-National Institute of Virology
20-A, Dr. Ambedkar Road P.B. No.11, Pune - 411001.
Telephone (off): 91-20-26006261
Fax : 91-20-6127669
Email : deeptiparasharster@gmail.com, Parashar.d@niv.co.in

Educational Qualifications:

- Ph.D, Microbiology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases, Agra (2004).

Discipline:

- Microbiology and Molecular Biology

Research Experience:

- Total 23 years

Awards / Fellowship:

- Endeavour Executive Fellowship, Nano Biotechnology Research Laboratory, Centre for Advanced Materials and Industrial Chemistry, RMIT University, Melbourne, Australia (13th March – 13th July 2016).
- ICMR-International Fellowship, Uniformed Services University of the Health Sciences, F. Edward Hébert School of Medicine, Bethesda, MD (1st April 2011 – 1st Oct 2011).

Employments

S. No.	Position/Designation	Duration	Name of Organization/Place of Work
1	Scientist 'E'	From 1 st Sep 2018	ICMR-National Institute of Virology Pune
2	Scientist 'D'	From 1 st Sep 2014	ICMR-National Institute of Virology Pune
3	Scientist 'C'	From 1 st Sep 2010	ICMR-National Institute of Virology Pune
4	Scientist 'B'	From 14 th Nov 2006	ICMR-National Institute of Virology Pune

Patent granted:

1. "Primers and method for identification of pathogenic mycobacteria", Indian Patent (No.242073, Grant Date: August 09, 2010).
2. "RNAi agent for inhibition of Chikungunya virus"
 - United States Patent granted on 21st Feb 2017 and patent no. allotted is US 9574195.
 - Chinese Patent granted on 22nd Oct 2019 and patent no. is ZL201480037556.6
 - European Patent granted on 11th Sep 2019 and patent no. is EP 3017046
 - Australian patent granted on 15th July 2021 and patent no. is 2014285701
 - Indian patent granted on 08th July 2021 and patent no. assigned is 371495

List of Publications

1. Alagarasu K, Tomar S, Patil J, Bachal R, More R, Bote M, Kakade M, Venkatesh V, **Parashar D***, Tandale BV* Seroprevalence of Dengue Virus Infection in Pune City in India, 2019: A Decadal change. J Infect Public Health. Available online 28 August 2023.
2. Shukla S, Jadhav SM, Gurav YK, **Parashar D***, Alagarasu K. Serum ferritin level as a prognostic biomarker for predicting dengue disease severity: A systematic review and meta-analysis [published online ahead of print, 2023 Jun 22]. Rev Med Virol. 2023;e2468. doi:10.1002/rmv.2468
3. Panda K, **Parashar D***, Viswanathan R. An Update on Current Antiviral Strategies to Combat Human Cytomegalovirus Infection. Viruses. 2023; 15(6):1358. <https://doi.org/10.3390/v15061358>
4. Kasabe B, Ahire G, Patil P, Puneekar M, Davuluri KS, Kakade M, Alagarasu K, **Parashar D*** and Cherian S (2023) Drug repurposing approach against chikungunya virus: an in vitro and in silico study. Front. Cell. Infect. Microbiol. 13:1132538. doi: 10.3389/fcimb.2023.1132538.
5. Joshi, R.K.; Agarwal, S.; Patil, P.; Alagarasu, K.; Panda, K.; Cherian, S.; **Parashar, D.**; Roy, S. Anti-Dengue Activity of Lipophilic Fraction of Ocimum basilicum L. Stem. Molecules 2023, 28, 1446. <https://doi.org/10.3390/molecules28031446>.
6. Alagarasu K, Puneekar M, Patil P, Kasabe B, Kakade M, Davuluri KS, Cherian S, **Parashar D***. Effect of carpaine, a major alkaloid from Carica papaya leaves, on dengue virus-2 infection and replication-an in-vitro and in-silico study. Phytother Res. 2023 Jan 1. doi: 10.1002/ptr.7715. Epub ahead of print. PMID: 36587936.
7. Joshi RK, Agarwal S, Patil P, Alagarasu K, Panda K, Parashar C, Kakade M, Sai DK, Cherian S, **Parashar D***, Pandey KC, Roy S. Effect of Sauropus androgynus L. Merr. on dengue virus-2: An in vitro and in silico study. J Ethnopharmacol . 2022; 1106044.

8. N Shrivastava, K Alagarasu, S Cherian*, **Parashar D***. Antiviral and platelet-protective properties of *Carica papaya* in dengue: a brief survey. *Indian J Med Res* September 2022 156(3):459-463.
9. Tagore R, Alagarasu K, Patil P, Pyreddy S, Polash SA, Kakade M, Shukla R, **Parashar D***. Targeted *in vitro* gene silencing of E2 and nsP1 genes of chikungunya virus by biocompatible zeolitic imidazolate framework. *Front. Bioeng. Biotechnol.* 10:1003448. doi: 10.3389/fbioe.2022.1003448
10. Patil P, Alagarasu K, Chowdhury D, Kakade M, Cherian S, Kaushik S, Yadav JP, Kaushik S, **Parashar D***. *In-vitro* antiviral activity of **Carica papaya** formulations against dengue virus type 2 and chikungunya viruses. *Heliyon.* 2022;8: e11879. <https://doi.org/10.1016/j.heliyon.2022.e11879>.
11. Madhura Puneekar, Bhagyashri Kasabe, Poonam Patil, Mahadeo Kakade, **Parashar D**, Kalichamy Alagarasu, Sarah Cherian. transcriptomics-based bioinformatics approach for identification and in-vitro screening of FDA-approved drugs for re-purposing against dengue virus-2. *Viruses.* 2022; 14, 2150. <https://doi.org/10.3390/v14102150>
12. Thomas N, Patil P, Sharma A, Kumar S, Singh VK, Alagarasu K, **Parashar D** and Tapryal S. Studies on the antiviral activity of chebulinic acid against dengue and chikungunya viruses and in silico investigation of its mechanism of inhibition. *Sci Rep* 12, 10397 (2022). <https://doi.org/10.1038/s41598-022-13923-6>.
13. Tomar SJ, Alagarasu K, More A, Nadkarni M, Bachal R, Bote M, Patil J, Venkatesh V, **Parashar D***, Tandale BV. Decadal Change in Seroprevalence of Chikungunya Virus Infection in Pune City, India. *Viruses.* 2022 May 7;14(5):998. doi: 10.3390/v14050998. PMID: 35632740.
14. Alagarasu K, Patil P, Kaushik M, Chowdhury D, Joshi RK, Hegde HV, Kakade MB, Hoti SL, Cherian S, **Parashar D***. In Vitro Antiviral Activity of Potential Medicinal Plant Extracts Against Dengue and Chikungunya Viruses. *Front Cell Infect Microbiol.* 2022 Apr 7;12:866452. doi: 10.3389/fcimb.2022.866452. PMID: 35463636; PMCID: PMC9021897.
15. Gurav YK, Alagarasu K, Yadav PD, Sapkal G, Gokhale M, **Parashar D**, Jadhav U, Bote M, Kakade M, Nyayanit D, Kumar A, Deshpande GR, Cherian S, Awate PS, Abraham P. First case of Zika virus infection during an outbreak of chikungunya in a rural region of Maharashtra state, India. *Trans R Soc Trop Med Hyg.* 2022 Apr 12:022. doi: 10.1093/trstmh/trac022. Epub ahead of print. PMID: 35415761.
16. Jeengar MK, Kurakula M, Patil P, More A, Sistla R, **Parashar D***. Effect of Cationic Lipid Nanoparticle Loaded siRNA with Stearylamine against Chikungunya Virus. *Molecules.* 2022 Feb 9;27(4):1170. doi: 10.3390/molecules27041170. PMID: 35208958; PMCID: PMC8877324.
17. Panda K, Alagarasu K, Patil P, Agrawal M, More A, Kumar NV, Mainkar PS, **Parashar D***, Cherian S. In Vitro Antiviral Activity of α -Mangostin against Dengue Virus Serotype-2 (DENV-2). *Molecules.* 2021 May 19;26(10):3016. doi: 10.3390/molecules26103016. PMID: 34069351; PMCID: PMC8158742..
18. Patil P, Agrawal M, Almelkar S, Jeengar MK, More A, Alagarasu K, Kumar NV, Mainkar PS, **Parashar D***, Cherian S. In vitro and in vivo studies reveal α -Mangostin, a xanthonoid from *Garcinia mangostana*, as a promising natural antiviral compound against chikungunya virus. *Virol J.* 2021 Feb 28;18(1):47. doi: 10.1186/s12985-021-01517-z. PMID: 33639977; PMCID: PMC7916311.

19. Panda K, Alagarasu K, **Parashar D**. Oligonucleotide-Based Approaches to Inhibit Dengue Virus Replication. *Molecules*. 2021 Feb 11;26(4):956. doi: 10.3390/molecules26040956. PMID: 33670247; PMCID: PMC7918374. (Impact Factor: 4.927).
20. Jeengar MK, Kurakula M, Patil P, More A, Sistla R, **Parashar D***. Antiviral activity of stearylamine against chikungunya virus. *Chem Phys Lipids*. 2021 Mar;235:105049. doi: 10.1016/j.chemphyslip.2021.105049. Epub 2021 Jan 7. PMID: 33422549.
21. Panda K, Alagarasu K, Cherian SS, **Parashar D***. Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2. *Indian J Med Res*. 2021 Jan & Feb;153(1 & 2):182-189. doi: 10.4103/ijmr.IJMR_2855_20. PMID: 33818475; PMCID: PMC8184069. (Impact Factor: 5.274)
22. Alagarasu K, Patil JA, Kakade MB, More AM, Yogesh B, Newase P, Jadhav SM, **Parashar D**, Kaur H, Gupta N, Vijay N, Narayan J, Shah PS; VRDL Team. Serotype and genotype diversity of dengue viruses circulating in India: a multi-centre retrospective study involving the Virus Research Diagnostic Laboratory Network in 2018. *Int J Infect Dis*. 2021 Oct;111:242-252. doi: 10.1016/j.ijid.2021.08.045. Epub 2021 Aug 21. PMID: 34428547.
23. Alagarasu K, Kakade MB, Bachal RV, Bote M, **Parashar D**, Shah PS. Use of whole blood over plasma enhances the detection of dengue virus RNA: possible utility in dengue vaccine trials. *Arch Virol*. 2021 Feb;166(2):587-591. doi: 10.1007/s00705-020-04892-0. Epub 2020 Nov 27. PMID: 33245437.
24. Kumar S, Singh VK, Vasam M, Patil P, Dhaked RK, Lohia NK, Ansari AS, **Parashar D**, Tapryal S. An in vitro refolding method to produce oligomers of anti-CHIKV, E2-IgM Fc fusion subunit vaccine candidates expressed in E. coli. *J Immunol Methods*. Available online 21 September 2020, 112869.
25. Kakade MB, Shrivastava N, Patil JA, **Parashar D**, Shah PS, Alagarasu K. Clinical evaluation of an in-house-developed real-time RT-PCR assay for serotyping of dengue virus. *Arch Virol* 2020; <https://doi.org/10.1007/s00705-020-04725-0>.
26. Newase P, More A, Patil J, Patil P, Jadhav S, Alagarasu K, Shah P, **Parashar D***, Cherian S. Chikungunya phylogeography reveals persistent global transmissions of the Indian Ocean Lineage from India in association with mutational fitness. *Inf Gen Evol* 2020; 82: 1042892 <https://doi.org/10.1016/j.meegid.2020.104289>
27. **Parashar D**, Rajendran V, Ramakrishna S, Shukla R. Lipid-based nanocarriers for delivery of small interfering RNA for therapeutic use. *Eur J Pharm Sci* 2020; 142:105159.
28. Sudeep AB, Vyas PB, **Parashar D** and Shil P. Differential susceptibility and replication potential of certain cell lines and one mosquito species to three lineages of chikungunya virus. *Indian J Med Res*. 2019; 149: 771-7.
29. Alagarasu K, Patil JA, Kakade, More AM, Bote M, Chowdhury D, Seervi M, Rajesh NT, Ashok M, Anukumar B, Abrahame AM, **Parashar D**, Shah PS. Spatio-temporal distribution analysis of circulating genotypes of dengue virus type 1 in western and southern states of India by a one-step real-time RT-PCR assay *Inf Gen Evol*. 2019; 75: 103989.
30. Alagarasu K, Jadhav SM, Bachal RV, Bote M, Kakade MB, Ashwini M, Singh A **Parashar D**. Scenario of dengue and chikungunya in Pune district, Maharashtra during 2016: A retrospective study based on data from samples referred to an Apex referral laboratory. *Dengue Bulletin* 2018; 40:33-43.

31. Abraham PR, **Parashar D**, Kasetty S, Sharma VD, Shivannavar CT. Characterization of nontuberculous mycobacteria isolated from environmental samples in Kalaburagi district of South India. JSM Microbiol 2018; 6: 1051.
32. Patil JA, Alagarasu K, Kakade MB, More AM, Gadekar KA, Jadhav SM, **Parashar D**, Shah PS. Emergence of dengue virus type 1 and type 3 as dominant serotypes during 2017 in Pune and Nashik regions of Maharashtra, Western India. Inf Gen Evol 2018; 66: 272-83.
33. Chauhan DS, Sharma R, **Parashar D**, Das R, Sharma P, Singh AV, Singh PK, Katoch K and Katoch VM. Rapid detection of Ethambutol Resistant *Mycobacterium tuberculosis* in clinical specimens by real time polymerase chain hybridization probe methods. Indian J Med Microbiol 2018; 36: 211-6.
34. **Parashar D***, Paingankar M, More A, Patil P. Altered microRNA expression signature in Chikungunya-infected mammalian fibroblast cells. Virus Genes 2018 <https://doi.org/10.1007/s11262-018-1578-8>.
35. **Parashar D***, Sudeep AB, More A, Patil P, Walimbe A, Mavale M, Amdekar S. Persistence of chikungunya virus in serum samples and infected mosquitoes stored at different temperatures. Current Science 2018; 115: 25-27.
36. Patil J, More A, Patil P, Jadhav S, Newase P, Agarwal M, Amdekar S, Raut CG, **Parashar D***, Cherian S. Genetic characterization of chikungunya viruses based on the E1 and E2 genes during the 2015-2017 outbreaks in different States of India. Arch Virol 2018; 163:3135-3140.
37. Amdekar S, **Parashar D**, Alagarasu K. Chikungunya virus induced arthritis: Role of host and viral factors in the pathogenesis Viral immunology 2017 30: 691-702.
38. Deoshatwar AR, **Parashar D***, Gokhale MD, More A. Low intensity Chikungunya outbreak in rural Western India indicates potential for similar outbreaks in other regions. Asian Pac J Trop Dis 2017; 7: 401-4.
39. Penumarthi A, **Parashar D**, Abraham AN, Dekiwadia C, Macreadie I, Shukla R and Smooker PM. Solid lipid nanoparticles mediated non-viral delivery of plasmid DNA to dendritic cells. J Nanoparticles Res. 2017; 19: 210. DOI 10.1007/s11051-017-3902-y.
40. **Parashar D*** and Cherian S. RNA interference agents as Chikungunya virus therapeutics. Future Virol 2016; 11: 321-9.
41. Damle RG, Jayaram N, Kulkarni SM, Nigade K, Khutwad K, Gosavi S and **Parashar D**. Diagnostic potential of monoclonal antibodies against the capsid protein of chikungunya virus for detection of recent infection. Arch Virol 2016. DOI 10.1007/s00705-016-2829-4.
42. Chauhan DS, Sharma R, **Parashar D**, Sharma P, Das R, Chahar M, Singh A, Singh PK, Katoch K and Katoch VM. Early detection of multidrug resistant (MDR) *Mycobacterium tuberculosis* in a single tube with in-house designed fluorescence resonance energy transfer (FRET) probes using real-time PCR. Indian J Exp Biol 2016; 54: 229-36.
43. Penumarthi A, **Parashar D**, Shukla R, Macreadie I and Smooker PM. Utilizing novel nanoparticles for DNA vaccine delivery. J Vaccines & Vaccination 12th Asia Pacific Global Summit and Expo on Vaccines & Vaccination. November 24-25, 2016 Melbourne, Australia J Vaccines Vaccin DOI: 10.4172/2157-7560.C1.045.

44. **Parashar D***, Amdekar S, More A, More R, Patil P and Ravindra Babu V. Chikungunya fever outbreak in Guntur, Andhra Pradesh, India (2013) *Indian J Med Res (Supplement)* 2015; 142: 62-6.
45. Gokhale MD, Paingankar MS, Sudeep AB and **Parashar D**. Chikungunya virus susceptibility and variation in populations of *Aedes aegypti* (Diptera: Culicidae) mosquito from India. *Indian J Med Res (Supplement)* 2015; 142: 33-43.
46. Dayaraj C, Kakade M; Alagarasu K, Patil J, Salunke A, **Parashar D** and Shah PS. Development of a quantitative multiplex reverse transcriptase polymerase chain reaction for detecting dengue virus and Chikungunya virus. *Archives Virol* 2015;160: 323-27.
47. **Parashar D***, Paingankar MS, Sudeep AB, More A, Shinde S and VA Arankalle. Assessment of qPCR, nested RT-PCR and ELISA techniques in diagnosis of Chikungunya. *Current Science* 2014; 107:2011-13.
48. Desikan P, Panwalkar N, **Parashar D**, Trivedi SK and Chauhan DS. Massive pericardial effusion caused by *Mycobacterium simiae*: First case report. *J Med Microbiol Case Reports*. 2014. <http://jmmcr.sgmjournals.org/content/1/3/e001040.full.pdf>.
49. **Parashar D*** and Cherian S. Antiviral Perspectives for Chikungunya Virus. *Biomed Res Int* 2014; 2014: 631642. <http://dx.doi.org/10.1155/2014/631642>.
50. **Parashar D**, Paingankar MS, Kumar S, Gokhale MD, Sudeep AB, Shinde SB and Arankalle VA. Administration of E2 and NS1 siRNAs inhibit Chikungunya virus replication in vitro and protects mice infected with the virus. *PLoS Negl Trop Dis* 2013. 7: e2405.
51. **Parashar D** and Patil D. Chikungunya: A disease re-emerged in India after 32 years. A review in Diamond jubilee publication of NIV Commemorative compendium 2012.
52. Mavale M, Sudeep AB, Gokhale MD, Hundekar SL, **Parashar D**, Ghodke YS, Arankalle VA and Mishra AC. Persistence of viral RNA in Chikungunya virus infected *Aedes aegypti* (Diptera: Culicidae) mosquitoes after prolonged storage at 28°C *Am J Trop Med Hyg*. 2012; 86:178-80.
53. **Parashar D**, Khalkar P and Arankalle VA. Survival of Hepatitis A and E Viruses in Soil Samples. *Clin Micro Infect*. 2011; 17: E1-E4.
54. Mavale M, **Parashar D**, Sudeep AB, Gokhale MD, Ghodke Y, Geevarghese G, Arankalle VA and Mishra AC. Venereal transmission of Chikungunya virus. *Am J Trop Med Hyg* 2010; 83:1242-4.
55. Jadaun GPS, Upadhyay P, Ahmed Z, Das R, **Parashar D**, Chauhan DS, Sharma VD, and Katoch VM. Utility of IS1245-IS1311 based PCR typing system for *Mycobacterium avium* isolates obtained from clinical and environmental sources. *J Bacteriol Res* 2010; 2: 005-8.
56. **Parashar D**, Das R, Chauhan DS, Sharma VD, Lavania M, Yadav VS, Chauhan SV and Katoch VM. Identification of environmental mycobacteria isolated from Agra, north India by conventional & molecular approaches. *Indian J Med Res*. 2009; 129: 424-31.
57. Sudeep AB, **Parashar D**, Jadi RS, Basu A, Mokashi C, Arankalle VA and Mishra AC. Establishment and characterization of a new *Aedes aegypti* (L.) (Diptera: Culicidae) cell line with special emphasis on virus susceptibility. *In Vitro Cell Dev Biol Anim*. 2009; 45: 491-5.

58. Dave S, Faujdar J, Kumar P, Gupta P, Das R, **Parashar D**, Chauhan DS, Natrajan M, Gupta UD, Katoch VM. Comparative growth pattern of multi drug resistance versus susceptible isolates of *Mycobacterium tuberculosis* in mice lungs. *Indian J Med Res* 2009; 130: 58-62.
59. Rajeshwari H, Nagveni S, Ajay Oli, **Parashar D**, Chandrakanth KR. Morphological changes of *Klebsiella pneumoniae* in response to Cefotaxime: a scanning electron microscope study. *World J Microbiol Biotechnol* 2009; 25: 2263-6.
60. Sudeep AB and **Parashar D**. Chikungunya: an overview. *J Biosci* 2008; 33:443-9.
61. Lavania M, Katoch K, **Parashar D**, Sharma P, Das R, Chauhan DS, Sharma VD and Katoch VM. Predominance of *Mycobacterium fortuitum-chelonae* complex in Ghatampur field area, endemic for leprosy. *Indian J Lepr* 2008; 80: 323-30.
62. **Parashar D**, Das R, Sharma VD, Chauhan DS and Katoch VM. Pathogenic rapidly growing: *Mycobacterium manitobense* in the environment of Agra, north India. *Indian J Med Res* 2007; 126: 230-2.
63. Chauhan DS, Sharma VD, **Parashar D**, Chauhan A, Singh D, Singh HB, Das R, Aggarwal BM, Malhotra B, Jain A, Sharma M, Kataria VK, Aggarwal JK, Hanif M, Shahani A and Katoch VM. Molecular typing of *Mycobacterium tuberculosis* isolates from different parts of India based on IS6110 element polymorphism using RFLP analysis. *Indian J Med Res* 2007; 125: 577-81.
64. Katoch VM, **Parashar D**, Chauhan DS, Singh D, Sharma VD and Ghosh S. Rapid identification of mycobacteria by gene amplification restriction analysis technique targeting 16S-23S ribosomal RNA internal transcribed spacer & flanking region. *Indian J Med Res* 2007; 125: 155-62.
65. **Parashar D**, Chauhan DS, Sharma VD and Katoch VM. Applications of real-time PCR technology to mycobacterial research. *Indian J Med Res* 2006; 124: 385-98.
66. **Parashar D**, Srivastava RK, Chauhan DS, Sharma VD, Singh M, Lavania M, Chauhan A, Bhatia AK and Katoch VM. Characterization of mycobacteria isolated from bovines by PRA-targeting hsp 65 gene region. *J Commun Dis* 2006; 38: 263-8.
67. **Parashar D**, Chauhan DS, Sharma VD, Chauhan A, Chauhan SV and Katoch VM. Optimization of procedures for isolation of mycobacteria from soil and water samples obtained in northern India. *Appl Environ Microbiol* 2004; 70: 3751-3.
68. Chauhan A, Chauhan DS, **Parashar D**, Gupta P, Sharma VD, Sachan AS, Gupta R, Agarwal BM and Katoch VM. DNA fingerprinting of *Mycobacterium tuberculosis* isolates from Agra region by IS 6110 probe. *Indian J Med Microbiol* 2004; 22: 238-40.
69. Chauhan DS, **Parashar D**, Das R, Sharma VD and Katoch VM. Confirmation of identification of non-tuberculous mycobacterial isolates by using 16S rRNA sequencing. *J Immunol Immunopathol* 2004; 6: 83-84.
70. **Parashar D**, Chauhan DS, Sharma VD, Chauhan A, Chauhan SVS and Katoch VM. Identification of mycobacteria at species level by PCR and restriction enzyme analysis by hsp65 gene. *J Immunol Immunopathol* 2004; 6: 84-85.
71. Chauhan A, **Parashar D**, Chauhan DS, Sharma VD, Agarwal BM and Katoch VM. PCR-ribotyping of pathogenic mycobacteria by an amplified ribosomal DNA fingerprinting assay. *J Immunol Immunopathol* 2004; 6: 139-140.
72. Katoch VM, Sharma VD, Chauhan DS, Singh D, **Parashar D**, Chauhan A and Gupta A. Protocol for rapid identification of pathogenic mycobacteria by gene amplification-Ribotyping. (2004).

73. Chauhan DS, Sharma VD, Singh HB, Das R, **Parashar D**, Chauhan A and Katoch VM (2003) DNA fingerprinting of Mycobacterium tuberculosis strains isolated from Northern parts of India using IS-6110 probe. In: Proceedings of the National Symposium on Biochemical Sciences: Health and Environmental Aspects (BSHEA-2003) (Ed. Satya Prakash, Faculty of Science, Dayalbagh Educational Institute - Deemed University, Agra), Allied Publishers Pvt. Ltd, New Delhi, p429-30.
74. **Parashar D**, Chauhan DS, Sharma VD, Das R, Singh HB, Chauhan A and Katoch VM (2003) Genomic analysis of variation in pathogenic mycobacteria by amplified ribosomal DNA fingerprinting techniques. In: Proceedings of the National Symposium on Biochemical Sciences: Health and Environmental Aspects (BSHEA-2003) (Ed. Satya Prakash, Faculty of Science, Dayalbagh Educational Institute -Deemed University, Agra), Allied Publishers Pvt. Ltd, New Delhi, p441-2.
75. **Parashar D** and Singh M. Gene amplification based methods for characterization of mycobacteria. Central JALMA Institute of Leprosy Quarterly Bulletin (2003).

Technology articles:

1. Sathe PS, Shah P, **Parashar D**, Patil K & Team. Booklet on Made-in-India Technologies (ICMR-NIV)" as a part of Bharat Ka Amrut Mahotsav: NIV DEN IgM Capture ELISA Kit.
2. Sathe PS, Shah P, **Parashar D**, Patil K & Team. Booklet on Made-in-India Technologies (ICMR-NIV)" as a part of Bharat Ka Amrut Mahotsav: NIV CHIK IgM Capture ELISA Kit.
3. Sathe PS, Shah P, **Parashar D**, Patil K & Team. Booklet on Made-in-India Technologies (ICMR-NIV)" as a part of Bharat Ka Amrut Mahotsav: NIV JE IgM Capture ELISA Kit.

Extramural Grants:

Completed:

- Studies on CHIKV - vector virus interactions, development of diagnostics, vaccine and prophylactics (as Principal Investigator; Duration: 2009-13, Funding agency: ICMR; Budget: Rs. 76, 50, 369).
- Study based on miRNA and host immune response to CHIK infection (as Mentor; Duration: 2014-16, Funding agency: DST; Budget: Rs. 21, 00, 000).
- Training program in the area of Modern Biology – under support to Indian Institutes (DHR): Molecular Virological Techniques for dengue and chikungunya (as Coworker, Funding agency: DHR, Budget: Rs. 1000000/ year).

Ongoing:

- Structure-based design and evaluation of the antiviral activity of potential lead compounds against the CHIKV (as Co-Investigator; Duration: 2017-2020; Funding agency: ICMR, Budget: 43.7 lakh)
- Use of lipid nanoparticles for effective delivery of siRNA against CHIKV (as Principal Investigator; Duration: 2017-2020; Funding agency: DST Nano Mission; Budget: Rs. 65,43,168).
- Monitoring of dengue and chikungunya viruses circulating in India for changes in the serotypes, genotype and lineages utilizing Viral Research & Diagnostic Laboratories Network (as Co-Coordination, Duration: 2018-2020; Funding agency: DHR-ICMR, Budget: Rs.7624000).

- Apex referral laboratory activity for National Vector Borne Disease Control Programme (as Coworker, Funding agency: NVBDCP, Budget: 300000 / year).
- Repurposing of drugs towards anti-Dengue and Chikungunya viruses using the systems biology approach (as Co-Principal Investigator; Duration: 2019-2022; Funding agency: ICMR; Budget: Rs. 2962400).
- Scaling up facilities for production of Diagnostic kits/ Reagents for detection of JE, DEN & CHIK viruses” kits (as Principal Investigator; Funding agency: NVBDCP)
- Complete genome sequencing and molecular characterization of circulating dengue viruses circulating in India using a next generation-based sequencing approach (as Co- investigator; Funding: DHR, Budget Rs. 24,97,000)
- An observational analytical prospective study on host and virus related variations associated with arthritis in chikungunya patients in North East India (as Principal investigator; Funding: ICMR, Budget: Rs.64,32,000)
- Development of mRNA based candidate vaccine for the prevention of chikungunya virus infection (as Co- investigator; Funding: DHR, Budget: Rs. 30,00,000)